Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
May 3, 2022 11:17 AM EDTUpdated 02:22 PM
Deals
Bioregnum

As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

Once again, Bio­gen’s board of di­rec­tors is look­ing to ex­e­cute a brisk turn­around in or­der to sat­is­fy in­vestors that it has a sol­id foot­ing and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times